Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . CS 康哲 药业 CHINA MEDICAL SYSTEM CHINA MEDICAL SYSTEM HOLDINGS LIMITED 康哲 藥業 控股 有限公司 " * ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 867 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 The Board of Directors ( the " Board " ) of China Medical System Holdings Limited ( the “ Company ” ) is pleased to announce the unaudited condensed consolidated results of the Company and its subsidiaries ( the " Group " or " CMS " ) for the six months ended 30 June 2021 ( the “ Reporting Period ” ) . Financial Highlights Turnover up 23.6 % to RMB3,843.0 million ( H1 2020 : RMB3,108.1 million ) ; in the case that all medicines were directly sold by the Group , turnover up 28.7 % to RMB4,269.3 million ( H1 2020 : RMB3,316.6 million ) Gross profit up 25.3 % to RMB2,873.8 million ( H1 2020 : RMB2,293.4 million ) ; in the case that all medicines were directly sold by the Group , gross profit up 27.9 % to RMB2,764.6 million ( H1 2020 : RMB2,161.7 million ) Profit for the period up 25.5 % to RMB1,631.6 million ( H1 2020 : RMB 1,300.5 million ) Basic earnings per share up 27.3 % to RMB0.6587 ( H1 2020 : RMB0.5174 ) As at 30 June 2021 , the Group's bank balances and cash amounted to RMB3,286.0 million while readily realizable bank acceptance bills amounted to RMB368.9 million Declared interim dividend up 25.5 % compared with the same period last year to RMB0.2641 per share ( H1 2020 : RMB0.2105 ) * For identification purpose only 1